Kwang Dong Pharmaceutical Co., Ltd. (009290.KS)
KRW 5670.0
(0.0%)
KRW 5670.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 48.76 Billion KRW | 7.93% |
| 2022 | 38.24 Billion KRW | -14.89% |
| 2021 | 44.93 Billion KRW | -3.55% |
| 2020 | 46.59 Billion KRW | 11.45% |
| 2019 | 41.8 Billion KRW | 23.15% |
| 2018 | 33.94 Billion KRW | -5.02% |
| 2017 | 35.73 Billion KRW | -19.49% |
| 2016 | 44.38 Billion KRW | -12.73% |
| 2015 | 50.86 Billion KRW | 0.81% |
| 2014 | 50.45 Billion KRW | 13.67% |
| 2013 | 44.38 Billion KRW | 22.15% |
| 2012 | 36.34 Billion KRW | -5.89% |
| 2011 | 38.61 Billion KRW | 0.82% |
| 2010 | 38.29 Billion KRW | 16.16% |
| 2009 | 32.97 Billion KRW | 10.32% |
| 2008 | 29.88 Billion KRW | -2.2% |
| 2007 | 30.55 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 5.04 Billion KRW | -70.4% |
| 2024 Q1 | 17.02 Billion KRW | 422.09% |
| 2023 FY | 41.27 Billion KRW | 7.93% |
| 2023 Q4 | 3.26 Billion KRW | -70.54% |
| 2023 Q3 | 11.07 Billion KRW | -7.17% |
| 2023 Q2 | 11.92 Billion KRW | -24.57% |
| 2023 Q1 | 15.81 Billion KRW | 40.73% |
| 2022 Q1 | 8.96 Billion KRW | -27.21% |
| 2022 Q2 | 10.31 Billion KRW | 15.05% |
| 2022 FY | 38.24 Billion KRW | -14.89% |
| 2022 Q3 | 11.38 Billion KRW | 10.41% |
| 2022 Q4 | 11.23 Billion KRW | -1.29% |
| 2021 Q3 | 14.91 Billion KRW | 62.2% |
| 2021 Q1 | 8.51 Billion KRW | 1.1% |
| 2021 Q2 | 9.19 Billion KRW | 8.06% |
| 2021 FY | 44.93 Billion KRW | -3.55% |
| 2021 Q4 | 12.31 Billion KRW | -17.46% |
| 2020 Q2 | 13.67 Billion KRW | 24.24% |
| 2020 Q3 | 13.49 Billion KRW | -1.29% |
| 2020 Q1 | 11 Billion KRW | 64.44% |
| 2020 FY | 46.59 Billion KRW | 11.45% |
| 2020 Q4 | 8.41 Billion KRW | -37.62% |
| 2019 Q1 | 12.38 Billion KRW | 83.21% |
| 2019 Q3 | 8.54 Billion KRW | -39.69% |
| 2019 FY | 41.8 Billion KRW | 23.15% |
| 2019 Q4 | 6.69 Billion KRW | -21.72% |
| 2019 Q2 | 14.17 Billion KRW | 14.44% |
| 2018 Q2 | 5.56 Billion KRW | -38.55% |
| 2018 Q3 | 12.57 Billion KRW | 126.18% |
| 2018 Q4 | 6.76 Billion KRW | -46.23% |
| 2018 FY | 33.94 Billion KRW | -5.02% |
| 2018 Q1 | 9.04 Billion KRW | 11.76% |
| 2017 Q1 | 9.66 Billion KRW | 37.6% |
| 2017 Q4 | 8.09 Billion KRW | -34.53% |
| 2017 Q3 | 12.36 Billion KRW | 120.26% |
| 2017 FY | 35.73 Billion KRW | -19.49% |
| 2017 Q2 | 5.61 Billion KRW | -41.89% |
| 2016 Q2 | 13.32 Billion KRW | 19.9% |
| 2016 Q3 | 12.93 Billion KRW | -2.91% |
| 2016 Q4 | 7.02 Billion KRW | -45.71% |
| 2016 FY | 44.38 Billion KRW | -12.73% |
| 2016 Q1 | 11.11 Billion KRW | 9.8% |
| 2015 Q4 | 10.11 Billion KRW | -31.47% |
| 2015 FY | 50.86 Billion KRW | 0.81% |
| 2015 Q3 | 14.76 Billion KRW | -3.38% |
| 2015 Q2 | 15.28 Billion KRW | 42.87% |
| 2015 Q1 | 10.69 Billion KRW | -9.95% |
| 2014 Q3 | 15.22 Billion KRW | 10.34% |
| 2014 Q2 | 13.79 Billion KRW | 44.18% |
| 2014 FY | 50.45 Billion KRW | 13.67% |
| 2014 Q1 | 9.56 Billion KRW | -9.7% |
| 2014 Q4 | 11.87 Billion KRW | -21.96% |
| 2013 Q3 | 14.86 Billion KRW | 34.72% |
| 2013 Q4 | 10.59 Billion KRW | -28.7% |
| 2013 FY | 44.38 Billion KRW | 22.15% |
| 2013 Q1 | 7.9 Billion KRW | -10.66% |
| 2013 Q2 | 11.03 Billion KRW | 39.54% |
| 2012 Q2 | 9.16 Billion KRW | 22.78% |
| 2012 Q3 | 10.68 Billion KRW | 16.63% |
| 2012 Q4 | 8.84 Billion KRW | -17.2% |
| 2012 FY | 36.34 Billion KRW | -5.89% |
| 2012 Q1 | 7.46 Billion KRW | 0.0% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q2 | 11.98 Billion KRW | 41.73% |
| 2011 Q3 | 9.76 Billion KRW | -18.53% |
| 2011 Q1 | 8.45 Billion KRW | -12.89% |
| 2011 FY | 38.61 Billion KRW | 0.82% |
| 2010 Q3 | 12.46 Billion KRW | 33.14% |
| 2010 Q2 | 9.36 Billion KRW | 38.3% |
| 2010 Q1 | 6.76 Billion KRW | -12.35% |
| 2010 Q4 | 9.7 Billion KRW | -22.1% |
| 2010 FY | 38.29 Billion KRW | 16.16% |
| 2009 FY | 32.97 Billion KRW | 10.32% |
| 2009 Q4 | 7.72 Billion KRW | -30.12% |
| 2009 Q3 | 11.05 Billion KRW | 42.0% |
| 2009 Q1 | 6.41 Billion KRW | 15.26% |
| 2009 Q2 | 7.78 Billion KRW | 21.3% |
| 2008 Q3 | 10.63 Billion KRW | 61.0% |
| 2008 Q2 | 6.6 Billion KRW | -2.07% |
| 2008 FY | 29.88 Billion KRW | -2.2% |
| 2008 Q4 | 5.56 Billion KRW | -47.66% |
| 2008 Q1 | 6.74 Billion KRW | 6.84% |
| 2007 Q4 | 6.31 Billion KRW | -41.57% |
| 2007 Q2 | 7.99 Billion KRW | 59.44% |
| 2007 Q1 | 5.01 Billion KRW | 0.0% |
| 2007 FY | 30.55 Billion KRW | 0.0% |
| 2007 Q3 | 10.8 Billion KRW | 35.06% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -13277.965% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 36.568% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 161.295% |
| HANDOK Inc. | 12.57 Billion KRW | -287.696% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 2551.691% |
| Yuhan Corporation | 74.56 Billion KRW | 34.595% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | -336.264% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 370.293% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 78.314% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -1495.769% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -239.834% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -8076.965% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -4960.116% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | -80.411% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -13277.965% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 728.769% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | -1109.026% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 169.718% |
| JW Holdings Corporation | 143.66 Billion KRW | 66.055% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 191.295% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 80.224% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 51.38% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 202.902% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | -604.03% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | -653.631% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | -458.533% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -13277.965% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 63.444% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 51.38% |
| Yuhan Corporation | 74.56 Billion KRW | 34.595% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | -133.113% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -1464.372% |
| Suheung Co., Ltd. | 42.99 Billion KRW | -13.426% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 51.38% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | -138.073% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 11.25% |
| CKD Bio Corp. | -20.15 Billion KRW | 341.993% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | -51.298% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | -92.742% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | -49.938% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 202.902% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | -47.126% |
| Boryung Corporation | 68.26 Billion KRW | 28.563% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 230.058% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -239.834% |
| JW Lifescience Corporation | 32.09 Billion KRW | -51.964% |